1. Home
  2. ARQT vs NMFC Comparison

ARQT vs NMFC Comparison

Compare ARQT & NMFC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ARQT
  • NMFC
  • Stock Information
  • Founded
  • ARQT 2016
  • NMFC 2010
  • Country
  • ARQT United States
  • NMFC United States
  • Employees
  • ARQT N/A
  • NMFC N/A
  • Industry
  • ARQT Biotechnology: Pharmaceutical Preparations
  • NMFC Finance/Investors Services
  • Sector
  • ARQT Health Care
  • NMFC Finance
  • Exchange
  • ARQT Nasdaq
  • NMFC Nasdaq
  • Market Cap
  • ARQT 1.1B
  • NMFC 1.3B
  • IPO Year
  • ARQT 2020
  • NMFC 2011
  • Fundamental
  • Price
  • ARQT $13.02
  • NMFC $11.98
  • Analyst Decision
  • ARQT Strong Buy
  • NMFC Hold
  • Analyst Count
  • ARQT 6
  • NMFC 2
  • Target Price
  • ARQT $17.00
  • NMFC $11.50
  • AVG Volume (30 Days)
  • ARQT 2.3M
  • NMFC 314.8K
  • Earning Date
  • ARQT 02-25-2025
  • NMFC 02-26-2025
  • Dividend Yield
  • ARQT N/A
  • NMFC 11.46%
  • EPS Growth
  • ARQT N/A
  • NMFC N/A
  • EPS
  • ARQT N/A
  • NMFC 1.04
  • Revenue
  • ARQT $138,708,000.00
  • NMFC $373,513,000.00
  • Revenue This Year
  • ARQT $217.37
  • NMFC $1.68
  • Revenue Next Year
  • ARQT $55.64
  • NMFC N/A
  • P/E Ratio
  • ARQT N/A
  • NMFC $11.50
  • Revenue Growth
  • ARQT 182.84
  • NMFC 4.95
  • 52 Week Low
  • ARQT $6.99
  • NMFC $10.62
  • 52 Week High
  • ARQT $16.20
  • NMFC $13.01
  • Technical
  • Relative Strength Index (RSI)
  • ARQT 50.16
  • NMFC 67.07
  • Support Level
  • ARQT $11.13
  • NMFC $11.80
  • Resistance Level
  • ARQT $13.62
  • NMFC $11.95
  • Average True Range (ATR)
  • ARQT 1.04
  • NMFC 0.14
  • MACD
  • ARQT 0.08
  • NMFC 0.03
  • Stochastic Oscillator
  • ARQT 67.26
  • NMFC 86.19

About ARQT Arcutis Biotherapeutics Inc.

Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate ZORYVE roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.

About NMFC New Mountain Finance Corporation

New Mountain Finance Corp is a closed-end, non-diversified management investment company. It invests in equity interests such as preferred stock, common stock, warrants, or options received in connection with debt investments or may include direct investment in the equity of private companies. The company's investment objective is to generate current income and capital appreciation through sourcing and origination of debt securities at all levels of the capital structure, including first and second-lien debt, notes, bonds, and mezzanine securities.

Share on Social Networks: